Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes  by Wen, Z.-H. et al.
Osteoarthritis and Cartilage 18 (2010) 1192e1202Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats:
association with changes of mitogen-activated protein kinase in chondrocytes
Z.-H. Wen y, C.-C. Tang z, Y.-C. Chang y, S.-Y. Huang y, S.-P. Hsieh x, C.-H. Lee k, G.-S. Huang{,
H.-F. Ng#, C.-A. Neoh#, C.-S. Hsieh yy, W.-F. Chen zz, Y.-H. Jean xx*
yDepartment of Marine Biotechnology and Resources, Asia-Paciﬁc Ocean Research Center, National Sun Yat-sen University, Kaohsiung, Taiwan
zDepartment of Early Childhood Education, National Pingtung University of Education, Taiwan
x Section of Pathology, Pingtung Christian Hospital, Pingtung, Taiwan
kDepartment of Orthopedics and Traumatology, Taipei Medical University Hospital, Taipei, Taiwan
{Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
# Section of Anesthesia, Pingtung Christian Hospital, Pingtung, Taiwan
yyDepartment of Surgery, Section of Pediatric Surgery, Pingtung Christian Hospital, Pingtung, Taiwan
zzDepartment of Neurosurgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
xx Section of Orthopedic Surgery, Pingtung Christian Hospital, Pingtung, Taiwana r t i c l e i n f o
Article history:
Received 16 November 2009
Accepted 18 May 2010
Keywords:
Glucosamine
Osteoarthritis
Nociception
Anterior cruciate ligament
MAPK* Address correspondence and reprint requests to
Orthopedic Surgery, Pingtung Christian Hospital, No. 6
900, Taiwan. Tel: 886-8-7368686; Fax: 886-8-733853
E-mail address: jean.tang@msa.hinet.net (Y.-H. Jea
1063-4584/$ e see front matter  2010 Osteoarthriti
doi:10.1016/j.joca.2010.05.012s u m m a r y
Objective: To study the effects of oral glucosamine sulfate on the development of osteoarthritis (OA) and
to examine concomitant changes in the nociceptive behavior of rats.
Methods: OA was induced in Wistar rats by anterior cruciate ligament transection (ACLT) of the right
knee; the left knee was untreated. The OAþ glucosamine group received oral glucosamine sulfate
(250 mg/kg/day) in a 2-g wafer once a day for 10 consecutive weeks starting at week 5 after ACLT. The OA
group was treated as above with 2-g wafers (placebo). The control group of naïve rats received 2-g wafers
only. The glucosamine alone group comprised naïve rats receiving glucosamine sulfate only. Nociceptive
behavior (mechanical allodynia and weight-bearing distribution of hind paws) during OA development
was analyzed pre- and 3, 6, 9, 12, 15, and 18 weeks post-ACLT. Macroscopic and histologic studies were
then performed on the cartilage and synovia. Immunohistochemical analysis was performed to examine
the effect of glucosamine on expression of mitogen-activated protein kinases (MAPKs) in the articular
cartilage chondrocytes.
Results: OA rats receiving glucosamine showed a signiﬁcantly lower degree of cartilage degeneration than
the rats receiving placebo. Glucosamine treatment also suppressed synovitis. Mechanical allodynia and
weight-bearing distribution studies showed signiﬁcant improvement in the OAþ glucosamine group as
compared to the OA group. Moreover, glucosamine attenuated p38 and c-Jun N-terminal kinase (JNK) but
increased extracellular signal-regulated kinase 1/2 (ERK) expression in OA-affected cartilage.
Conclusion: Our results indicate that treatment with oral glucosamine sulfate in a rat OA model (1)
attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates
chondrocyte metabolism, possibly through inhibition of cell p38 and JNK and increase of ERK expression.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA), characterized by the progressive degrada-
tion of articular cartilage, is a complex disorder that can affect the
majority of joints in the body. Although OA is classically deﬁned as: Yen-Hsuan Jean, Section of
0 Ta-Lan Road, Pingtung City
6.
n).
s Research Society International. Pa progressively degenerative disease of articular cartilage, the key
role of inﬂammation in the pathogenesis of OA has been identiﬁed1.
Although the pain associated with OA is primarily localized to the
joint, a number of OA patients have exhibited increased nociception
in adjacent or even remote body areas2,3. This phenomenon,
referred to as secondary hyperalgesia or allodynia, is thought to be
the result of nociceptive/central sensitization4.
Glucosamine is an amino monosaccharide nutrient and
precursor of the glycosaminoglycan disaccharide unit, which is the
building block of the proteoglycan component of the cartilage
matrix. In human OA patients, administration of 1500 mg ofublished by Elsevier Ltd. All rights reserved.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 18 (2010) 1192e1202 1193glucosamine/day for 3 years prevented joint-space loss and
relieved symptoms when compared to placebo, suggesting that
glucosamine possesses some anti-inﬂammatory activity that can
alter disease progression5. Glucosamine has wide availability,
relatively low cost, absence of known side effects, high oral
absorption rate (>87% in dogs and cats), and is readily transferred
into cartilage6. Glucosamine sulfate is the most frequently used
form of glucosamine for the treatment of OA5,7, but its efﬁciency in
the treatment of OA is still controversial8. However, despite the
widespread use of glucosamine by patients with OA in clinical
practice, the role of glucosamine in the development of OA and OA-
induced nociception has not been well elucidated.
Mitogen-activated protein kinases (MAPKs) are a family of
serine/threonine kinases that are part of the signal transduction
pathways connecting inﬂammatory and other extracellular signals
to intracellular responses9. The MAPK family consists of p38 kinase,
c-Jun N-terminal kinase (JNK), and the extracellular signal-regu-
lated kinases 1/2 (ERKs). The JNK and p38 kinases are activated in
response to inﬂammatory cytokines such as interleukin (IL)-1 and
tumor necrosis factor (TNF)10,11, while ERK mediates signaling by
cytokines and growth factors12,13. Inhibitors of p38, JNK, and ERK
are under development for treatment of arthritis, and they have
shown efﬁcacy in experimentally induced arthritis and joint
pain9,13e16. However, the in vivo effects of glucosamine sulfate on
cartilage MAPK activity in the pathogenesis of OA are still
unknown. In the present study, we investigated the effects of oral
glucosamine sulfate on nociception of the knee joint as assessed by
mechanical allodynia and hind paw weight distribution in an
experimental rat OA model. Gross morphology and histopathology
were examined in the cartilage and synovia. Immunohistochemical
analysis was performed to examine the effect of glucosamine
sulfate on MAPK expression in articular cartilage chondrocytes.
Methods
Animals
Two-month-old male Wistar rats (body weight¼ 275e315 g)
were used and maintained on a 12-h light-dark cycle under
climate-controlled conditions of 22e24C with a relative humidity
of 50e55%. Animals with pre-existing anatomical or gait abnor-
malities were excluded. The use of rats conformed to the Guiding
Principles in the Care and Use of Animals as approved by the
Council of the American Physiology Society and was approved by
the National Sun Yat-sen University Animal Care and Use
Committee (approval number 96004).
Surgical technique for induction of OA
OAwas induced in rats by anterior cruciate ligament transection
(ACLT) of right knee; the left knee was untreated. The surgical
procedure is modiﬁed from the protocol described by previous
study17. The animals were not immobilized after surgery and were
allowed daily unrestricted cage activity.
Experimental design
Five weeks after ACLT, the animals were divided into four
groups. The OAþ glucosamine group received oral glucosamine
sulfate (Sigma, St. Louis, MO; 250 mg/kg/day) in a 2-g wafer once
a day for 10 consecutiveweeks starting at week 5 after ACLT. The OA
group was treated as above except that they received 2-g wafers
alone (placebo). The control group comprised naïve rats receiving
2-g wafer only. The glucosamine alone group was made up of naïve
rats receiving glucosamine sulfate (250 mg/kg/day in wafer) oncea day for 10 consecutive weeks. Nociceptive behavior (mechanical
allodynia and weight-bearing distribution on the hind paws)
during OA development was analyzed, and changes of knee joint
width were measured pre- and 3, 6, 9, 12, 15, and 18 weeks post-
ACLT, following which the animals were sacriﬁced. Gross
morphology and histopathology were examined in the femoral
condyles, tibial plateau, and synovia. The sample sizes of the
control, OA, OAþ glucosamine, and glucosamine alone groups were
6, 12, 12, and 6, respectively.
Assessment of nociception
The effect on pain was assessed by mechanical allodynia and
weight-bearing distribution of hind paws were measured pre- and
3, 6, 9, 12, 15, and 18 weeks after ACLT.
Mechanical allodynia
In the mechanical allodynia, paw withdrawal thresholds to
mechanical stimulus were determined using the up and down
method by applying calibrated von Frey ﬁlaments (North Coast
Medical, Inc. Morgan Hill, CA, USA)18. The diameters of the ﬁla-
ments corresponded to a logarithmic scale of the force exerted, and
thus the perceived intensity could be measured on a linear and
interval scale. The withdrawal threshold was determined by
Chaplan’s “up-down” method involving the use of alternate large
and small ﬁbers to determine the 50%withdrawal threshold18. Each
von Frey hair was applied to the plantar surface of the paw for 5 s.
The von Frey ﬁlament was applied to each paw for ﬁve trials at
approximately 3-min intervals. Any sign of discomfort (vocaliza-
tion, ﬂinching) or attempt of the animal to withdraw the paw was
considered positive response.
Weight-bearing distribution test
The effect of joint damage on the weight distribution through
the right and left knees wasmeasured using a Dual ChannelWeight
Averager (Singa Technology Corporation, TW) which indepen-
dently measures the weight bearing to each hind paw. Changes in
hind paw weight distribution between the right and the left limbs
were utilized as an index of joint discomfort in the OA knee19,20. The
percent weight distributed onto the right hind paw was calculated
by the following equation: [weight on right hind paw/(weight on
right hind pawþweight on left hind paw)] 100. The quantitative
method was according to previous study21.
Inﬂammation, gross morphology, and histopathological examination
of the knee joints
The width of the bilateral hind limb knee joints was measured
from the medial to the lateral aspect of the joint line by using
calipers before (baseline) and 3, 6, 9,12,15, and 18weeks after ACLT.
The gross morphological changes in the cartilage were examined
according to previously described methods22. The joints were
sectioned 0.5 cm above and below the joint line, ﬁxed in 10%
neutral buffered formalin for 3 days, and then decalciﬁed for 2
weeks in buffered 12.5% ethylenediaminetetraacetic acid (EDTA)
and formalin solution. The cartilage was stained with hematox-
ylineeosin (H & E) and Safranin-O/fast green stains to assess the
general morphology and matrix proteoglycans. Microscopic
examination of the articular cartilage of the medial and lateral
femoral condyles and the tibial plateau was graded according to
Mankin’s grading system23. A representative specimen of the
synovial membrane from the medial and lateral compartments of
Fig. 1. Time course of the anti-allodynic effect of glucosamine sulfate in the ACLT-OA
nociceptive model. (A) In mechanical allodynia, the time required to elicit hind paw
withdrawal in the OAþ glucosamine group was signiﬁcantly increased compared with
OA rats at 15 and 18 weeks after ACLT. (B) The time course of the % weight bearing of
the right (ACLT) hind paw for 18 weeks after ACLT. A signiﬁcant difference was noted
between OA and OAþ glucosamine groups at 15 and 18 weeks after surgery. In the
glucosamine alone (naïve rats treated with glucosamine sulfate alone) group, similar
changes are observed, as in the control group. Data shown represent the mean (95%
conﬁdence interval) of the ipsilateral hind paw of each group.
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examination, as previously described24.
Immunohistochemistry for p38, JNK, and ERK MAPKS
Immunohistochemical analysis was performed to examine the
effect of glucosamine sulfate on p38, JNK, and ERK expression in the
articular cartilage chondrocytes. Cartilage specimens were pro-
cessed for immunohistochemical analysis as described in previous
studies25,26. Brieﬂy, sections (2 mm) of the parafﬁn-embedded
specimens were placed on slides, deparafﬁnized with xylene, and
dehydrated in a graded series of ethanol, following which endog-
enous peroxidase activity was quenched by 30-min incubation in
0.3% hydrogen peroxide. The antigen was retrieved by enzymatic
digestionwith proteinase K (20 mM; Sigma) in phosphate-buffered
saline (PBS) for 20 min. After washing in ice-cold PBS, slides were
incubated overnight at 4Cwith anti-phospho-p38 (Thr180/Tyr182,
1:100 dilution; catalog no. 9211), anti-ERK (Thr202/Tyr204, 1:100
dilution, catalog no. 9101), or anti-JNK (Thr183/Tyr185, 1:100
dilution, catalog no. 9258) in a humidiﬁed chamber. All the anti-
bodies were obtained from Cell Signaling Technology Inc. (Beverly,
MA). The sections were incubated for 90 min with biotinylated
anti-rabbit IgG (Vector Laboratories, Burlingame, CA) diluted 200
times in 1% bovine serum albumin (BSA) in PBS.
The antigens present in the each cartilage specimen were
quantiﬁed using our previously published method26 and estimated
by determining the number of chondrocytes that stained positive in
the entire thickness of cartilage according to procedures in previous
studies14,27. The cartilage was divided into six microscopic ﬁelds
(three each in the superﬁcial and deep zones, magniﬁcation 400),
and the results were averaged. For each OA specimen, it was
ensured prior to evaluation that an intact cartilage surface could be
detected and used as a marker for the validation of the morpho-
metric analysis. The ﬁnal results were expressed as the percentage
of chondrocytes staining positive for the antigen (cell score), with
the maximum score for each cartilage specimen being 100%. Each
slidewas reviewed by two independent readers (HSYand HSP) who
were blinded to the treatment groups. The combined data obtained
from themedial and lateral femoral condyle and tibial plateau were
considered for statistical analysis (six rats per group).
Data and statistical analysis
All data were presented as mean (95% conﬁdence interval). The
datawere analyzed by using one-way analysis of variance (ANOVA),
followed by StudenteNewmaneKeuls post hoc test (SigmaStat 2.03,
for Windows). Differences resulting in P-values of less than 0.05
were considered signiﬁcant.
Results
No signs of drug toxicity were noted in the rats treated with
glucosamine sulfate. The level of daily activity was similar in all
three experimental groups, and there were no signiﬁcant differ-
ences in body weight between the groups over the study period.
Nociceptive behavior (mechanical allodynia and weight-bearing
distribution) in OA
Figure 1(A) shows the effect of oral glucosamine sulfate on
mechanical allodynia compared with placebo in ACLT-induced OA
rats. At 15 and 18 weeks after ACLT-induced OA, the force required
for hind paw withdrawal in the OA þ glucosamine group was
signiﬁcantly higher than that in the OA group [7.7 (6.4e9.0) vs 5.3
(3.5e7.1) g, P¼ 0.027 and 8.0 (6.5e9.5) vs 5.0 (4.1e5.9) g, P¼ 0.001,respectively] [Fig. 1(A)]. Eighteen weeks after the induction of OA,
the mechanical threshold in the hind paw of the side contralateral
to the side of ACLT was 10.8. (9.6e12.0), 11.7 (10.1e13.3) and 12.5
(9.9e15.1) g in the OA, OA þ glucosamine, and control groups,
respectively. Before ACLT (baseline values), the mechanical
threshold in the hind paw on the side contralateral to the ACLT side
was 11.7 (10.1e13.3), 11.7 (10.1e13.3), and 12.5 (9.9e15.1) g for the
OA, OA þ glucosamine, and control groups, respectively. Glucos-
amine alone did not change the mechanical allodynia behavior.
In theweight-bearing distribution test, the %weight on the right
hind paw was reduced at 3, 6, 9, 12, 15, and 18 weeks after ACLT
compared to that in the control group [Fig. 1(B); P< 0.001,
P< 0.001, P< 0.001, P¼ 0.003, P< 0.001, and P< 0.001, respec-
tively]. The OAþ glucosamine group showed signiﬁcantly higher %
weight on the right hind paw than that of the OA group at 12, 15,
and 18weeks after surgery [45.6% (43.2e48.0) vs 41.2% (38.7e43.7),
P¼ 0.011; 46.2% (43.8e48.6) vs 39.3% (37.0e41.8), P< 0.001; 45.3%
(43.2e47.3) vs 38.2% (36.1e40.9), P< 0.001, respectively].
Table I
Macroscopic evaluation of the articular cartilage of the femoral condyles and tibial
plateau
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hind limb weight bearing was noted of 12, 15, and 18 weeks after
ACLT.Groups Macroscopic score P-Value
Comparison
vs control
Comparison
vs OA
Control 0.4 (0.3e0.4) e <0.001
OA 2.6 (2.1e3.0) <0.001 e
OAþ glucosamine 1.6 (1.0e2.1) 0.005 0.005
Glucosamine alone 0.5 (0.4e0.5) 0.053 0.001
Data are expressed as mean (95% conﬁdence interval). For the macroscopic score,
refer to Methods. OA: ACLT-induced OA knee treated with wafer; OAþ glucos-
amine: OA knee treated with glucosamine sulfate; control: naïve rats receiving
wafer only; glucosamine alone group: naïve rats receiving glucosamine sulfate only.Knee joint width and gross morphologic changes
In knee joint width changes, as shown in Fig. 2, with a signiﬁcant
difference between the control group and both OAþ glucosamine
and OA groups at 6, 9,12,15, and 18weeks after the ACLT. Thewidth
of the hind limb knee joint of the OAþ glucosamine group was
signiﬁcantly lower than that of the OA group at 12,15, and 18weeks
after surgery [0.5 (0.4e0.6) mm vs 1.2 (1.0e1.3) mm, P< 0.001; 0.6
(0.5e0.7) mm vs 1.1 (1.0e1.3) mm, P< 0.001 and 0.7 (0.5e0.8) mm
vs 1.3 (1.1e1.4) mm, P< 0.001, respectively] (Fig. 2). In the OA
group, gross characteristics of cartilage degeneration, such as
ﬁbrillation, erosion and ulcer formation, and osteophytes forma-
tion, were seen in the femoral condyle and tibial plateau. Markedly
less severity of cartilage damage was seen in the OAþ glucosamine
group. In the control and glucosamine alone groups, the cartilage of
the femoral condyle and tibial plateau was macroscopically normal,
with a glistening, smooth surface, and no cartilage defects or
osteophytes were observed. A signiﬁcant difference in gross
morphologic score was found between the OA group and both
OAþ glucosamine and control groups (Table I; P¼ 0.005 and
P< 0.001, respectively), but not between the control group and
glucosamine alone group (P¼ 0.053). The grade of cartilage damage
in the OAPPþ glucosamine group was signiﬁcantly lower than that
in the OA group (Table I; P¼ 0.005). Synovia from the OA group
were hypertrophic and showed a reddish-yellow discoloration,
whereas in the OAþ glucosamine group, they were thinner and the
discoloration was less intense. Synovia from the control group had
a white luster and transparent appearance, with no hyperemia or
evidence of synovitis.Microscopic ﬁndings
The cartilage of the control and glucosamine alone groups had
a normal histological appearance. A thin, glistening, smooth lamina
ﬁlled with ﬂattened chondrocytes was observed, and no loss of
proteoglycan was seen in the matrix on Safranin-O staining [Fig. 3
(A)]. Specimens from the OA group showed obvious histologicalFig. 2. Time course of joint width changes after ACLT. The widths of the bilateral hind
limb knee joints were measured in each rat before and again at 3, 6, 9, 12, 15, and 18
weeks after ACLT. The data are expressed as the difference in knee widths between the
values at each time point and at time zero (before surgery). In the glucosamine alone
group, changes similar to those in the control group are observed. Data presented as
mean (95% conﬁdence interval).changes, including complete disorganization, moderate-to-severe
hypocellularity, proteoglycan reduction on Safranin-O/fast green
staining, and denudation of articular surface and ﬁssures extending
into the deep zones [Fig. 3(B)]. Osteophytes were present at the
medial margins of the femoral condyle and tibial plateau. In the
OAþ glucosamine group, there was marked reduction in
the severity of the femoral condyle and tibial plateau lesions: only
ﬁbrillation and ﬁssures extending into the superﬁcial layer of
cartilage were observed [Fig. 3(C)]. In the glucosamine alone group
[Fig. 3(D)], similar changes are observed as in the control group.
Mankin’s score for the OAþ glucosamine group was signiﬁcantly
lower than that for the OA group. Signiﬁcant differences were
found between the control and both OA and OAþ glucosamine
groups (Table II). Cartilage degeneration was more severe at the
medial sides than at the lateral sides of the femoral condyle and
tibial plateau in the OA group (Table II). Synovia from the OA group
were thick, had focal villi, and showed hyperplasia of the lining
cells and moderate inﬁltration of mononuclear inﬂammatory cells.
The histology of the synovia from the control and glucosamine
groups was within normal limits. The synovitis scores on micro-
scopic evaluation are shown in Table II; signiﬁcant differences were
found between the control group and both OA and OAþ glucos-
amine groups and between the OAþ glucosamine group and the
OA group (Table II). The synovitis score was lower for the OAþ -
glucosamine group than the OA group (P< 0.001), suggesting that
synovial inﬂammation was less severe in the OAþ glucosamine
group. The reductions resulted primarily from a less marked degree
of synovial hyperplasia.
Immunohistochemistry of phospho-p38, phospho-JNK, and
phospho-ERK MAPKS in articular cartilage
The immunolocalization of phosphorylated MAPK (phospho-
p38, phospho-JNK, and phospho-ERK) protein expression in carti-
lage specimens from the control, OA, OAþ glucosamine, and
glucosamine alone groups was examined using the appropriate
antibodies (Figs. 4e6). As shown in Fig. 4, fewer positive phospho-
p38 chondrocytes were observed in the control group [Fig. 4(A)]
than in the OA group [Fig. 4(B)]. In the OA group at 18 weeks after
ACLT, positive phospho-p38 immunoreactive chondrocytes were
apparently increased in the superﬁcial and transitional cartilagi-
nous zones [Fig. 4(B)]. Oral glucosamine inhibited OA-induced
upregulation of phospho-p38 expression in chondrocytes of carti-
lage [Fig. 4(C)]. Glucosamine alone did not produce signiﬁcant
changes of phospho-p38 expression in cartilage specimens [Fig. 4
(D)]. Quantiﬁcation of the number of immunoreactive phospho-
p38 cells showed that glucosamine signiﬁcantly inhibited OA-
induced upregulation of phospho-38epositive chondrocytes [Fig. 4
(F); P¼ 0.002].
Fig. 3. Histopathological evaluation of the articular cartilage of the femoral condyles and tibial plateau. (A) In the control group, the surface of the superﬁcial cartilaginous layer is
smooth, and the cartilage matrix is consistently well stained with Safranin-O/fast green. (B) The specimen from the OA group shows a decrease in the cartilage thickness,
disappearance of the surface layer cells (arrow), a ﬁssure extending into the transitional and radial zones, and chondrocyte hypocellularity in the transitional and radial zones.
(C) The specimen from the OAþ glucosamine group shows mild irregularity of the surface layer, ﬁbrillation of and ﬁssures in the superﬁcial cartilaginous layer (arrow), and slight
diffuse hypercellularity in the transitional and radial zones. (D) In the glucosamine alone group, similar changes are observed, as in the control group. Scale bar¼ 500 mm.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 18 (2010) 1192e12021196As shown in Fig. 5, only a very small number of chondrocytes
stained positive for phospho-JNK in cartilage specimens in the
control and glucosamine alone groups [Fig. 5(A and D)]. In the OA
specimens, phospho-JNK protein expression was clearly seen in
chondrocytes within the superﬁcial and transitional cartilage,
similar to the ﬁndings in phospho-p38 expression [Fig. 5(B)]. TheTable II
Histological evaluation scores of the articular cartilage and synovial membrane as obtain
Group Control OA
Location
Femoral condyle
Medial side 1.4 (0.4e2.4) 8.5 (6
Comparison vs control: P-value e <0.0
Comparison vs OA: P-value <0.001 e
Lateral side 1.2 (0.1e2.5) 8.1 (6
Comparison vs control: P-value e <0.0
Comparison vs OA: P-value <0.001 e
Tibial plateau
Medial side 1.1 (0.1e2.3) 7.8 (6
Comparison vs control: P-value e <0.0
Comparison vs OA: P-value <0.001 e
Lateral side 0.9 (0.0e1.8) 7.2 (6
Comparison vs control: P-value e <0.0
Comparison vs OA: P-value <0.001 e
Synovial membrane 1.5 (0.1e3.1) 8.3 (6
Comparison vs control: P-value e <0.0
Comparison vs OA: P-value <0.001 e
Data are expressed as mean (95% conﬁdence interval). For deﬁnitions of the osteoarthrit
treated with wafer; OAþ glucosamine: ACLT-induced OA knee treated with glucosamine
receiving glucosamine sulfate only.phospho-JNK protein expressionwas signiﬁcantly increased in both
the OA and OAþ glucosamine groups compared with the control
group (Fig. 5(F); P< 0.001 and P¼ 0.007, respectively). Glucos-
amine signiﬁcantly inhibited OA-induced upregulation of phospho-
JNK expression in chondrocytes of cartilage [Fig. 5(C and F),
P¼ 0.006].ed by light microscopy
OAþ glucosamine Glucosamine alone
.0e11.0) 3.6 (2.8e4.4) 1.6 (0.8e2.4)
01 0.002 0.710
<0.001 <0.001
.1e10.1) 3.3 (2.8e3.8) 1.2 (0.7e1.7)
01 <0.001 1.000
<0.001 <0.001
.1e9.5) 2.7 (1.9e3.5) 1.5 (0.7e2.3)
01 0.020 0.488
<0.001 <0.001
.2e8.2) 2.5 (2.0e3.0) 0.8 (0.3e1.3)
01 0.001 0.817
<0.001 <0.001
.3e10.3) 3.5 (2.7e4.3) 1.4 (0.6e2.2)
01 0.010 0.888
<0.001 <0.001
ic score (Mankin) and synovitis score, refer to Methods. OA: ACLT-induced OA knee
sulfate; control: naïve rats receiving wafer only; glucosamine alone group: naïve rats
Fig. 4. Distribution of phospho-p38 protein immunoreactivity in the cartilage of the control, OA, OAþ glucosamine, and glucosamine alone groups. Positive immunoreactivity of the
phospho-p38 protein is indicated by the red-brown color (arrows). Distribution of anti-p38 immunoreactivity in the cartilage of the (A) control, (B) OA, (C) OAþ glucosamine, and
(D) glucosamine alone groups and (E) the negative control from OA. All were stained with antibodies against the phospho-p38 protein. (F) Quantitative analysis showed that
glucosamine signiﬁcantly reduced the ACLT-induced increase in the number of p38-positive chondrocytes in cartilage of the OA knee. The data were presented as mean (95%
conﬁdence interval). Scale bar¼ 100 mm.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 18 (2010) 1192e1202 1197Figure 6 shows the distribution of phospho-ERK-positive cells in
cartilage from the control [Fig. 6(A)], OA [Fig. 6(B)], OAþ glucos-
amine [Fig. 6(C)], and glucosamine alone groups [Fig. 6(D)]. When
compared with the control group, the number of positive phospho-
ERK chondrocytes was upregulated in the OAþ glucosamine andglucosamine alone groups (P< 0.001). A slightly decreased
phospho-ERK expression was seen in the OA specimen at 18 weeks
after ACLT [Fig. 6(F), P¼ 0.438]. In all four individual treatment
groups, no staining was observed in the phospho-p38, phospho-
JNK, or phospho-ERK negative controls.
Fig. 5. Distribution of phospho-JNK protein immunoreactivity in the cartilage of the control, OA, OAþ glucosamine, and glucosamine alone groups. Positive immunoreactivity of the
JNK protein is indicated by the red-brown color (arrows). Distribution of anti-phospho-JNK immunoreactivity in the cartilage of the (A) control, (B) OA, (C) OAþ glucosamine, and
(D) glucosamine alone groups and (E) the negative control from OA. All were stained with antibodies against the phospho-JNK protein. Scale bar¼ 100 mm. (F) Quantitative analysis
showed that glucosamine sulfate signiﬁcantly reduced the ACLT-induced increase in the number of phospho-JNK-positive chondrocytes in cartilage of the OA knee. The data were
presented as mean (95% conﬁdence interval). Scale bar¼ 100 mm.
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To our knowledge, this is the ﬁrst study to demonstrate that oral
glucosamine sulfate can attenuate the development of OA and
associated nociceptive behaviors (such as mechanical allodynia and
weight-bearing distribution) in an experimental rat OA model.More interestingly, glucosamine sulfate inhibited p38 and JNK but
enhanced ERK MAPK expression in the articular cartilage chon-
drocytes in the experimental OA model.
The destabilizing effect secondary to the ACLT has been used as
a model for the study of joint alterations that closely resemble
those of human OA28. This include superﬁcial ﬁbrillation,
Fig. 6. Distribution of phospho-ERK protein immunoreactivity in the cartilage of the control, OA, OAþ glucosamine, and glucosamine alone groups. Positive immunoreactivity of the
phospho-ERK protein is indicated by the red-brown color (arrows). Distribution of anti-phospho-ERK immunoreactivity in the cartilage of the (A) control, (B) OA, (C) OAþ glu-
cosamine, and (D) glucosamine alone groups and (E) the negative control from OAþ glucosamine. All were stained with antibodies against the phospho-ERK protein. Scale
bar¼ 100 mm. (F) Quantitative analysis showed that glucosamine sulfate signiﬁcantly enhanced the number of phospho-ERK-positive chondrocytes in cartilage of the ACLT-induced
OA knee. The data were presented as mean (95% conﬁdence interval). Scale bar¼ 100 mm.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 18 (2010) 1192e1202 1199disorganization of the collagen and proteoglycans network, joint
capsule thickening, and osteophyte formation28. Glucosamine
protects against subchondral bone change during the develop-
ment of early phase of ACLT-induced OA suggest a possible
mechanism of glucosamine to partially protect cartilage fromdegeneration29. In our present study, glucosamine sulfate atten-
uated the development of OA compared to placebo treatment
(Tables I and II; Fig. 3). This is in accordance with a previous
animal study, that glucosamine is able to reduce cartilage degra-
dation following ACLT in rabbits30.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 18 (2010) 1192e12021200Patients with arthritis of the knee joints usually experience
a pain sensation when the inﬂamed knee joints bear weight or are
mechanically stimulated by being moved or pressed31. Lee et al.
showed that intra-articular injection of magnesium sulfate could
attenuate the nociceptive behavior such as mechanical allodynia
and thermal hyperalgesia in a collagenase induced OA rat model26.
In the present study, ACLT-induced nociceptive behavior was
characterized by a decrease in mechanical allodynia threshold and
decrease weight-bearing distribution in the injured hind paw
(Fig. 1). In the OAþ glucosamine group, signiﬁcant improved
mechanical allodynia at 15 and 18 weeks, and hind paw weight-
bearing distribution were noted at 12, 15, and 18 weeks after ACLT,
respectively, when compared with OA group (Fig. 1). This is partial
in accordance with a previous study that used a quantitative joint
pain associated to weight bearing in the ACLT model in rats32. We
believe that pain on weight bearing, as assessed in the present
study, represents a major component of the multifactorial mecha-
nism of joint pain in OA.
The ability of glucosamine-containing nutraceuticals to reduce
proteoglycan loss, impede cartilage degeneration, delay joint-space
narrowing, and improve pain has been extensively reported5,33.
Glucosamine treatment upregulates transforming growth factor
(TGF)-b1mRNA levels in chondrocytes, and it can preserve cartilage
and promote its repair upon damage34. Glucosamine has been
shown to suppress prostaglandin E2 (PGE2) production in chon-
drocytes and synoviocytes from OA joints35. It also blocked IL-1-
induced expression of matrix-speciﬁc proteases such as matrix
metalloproteinase (MMP)-3, MMP-9, MMP-10, MMP-12, and
aggrecanase36. Glucosamine inhibits aggrecanase activity via
suppression of glycosylphosphatidylinositol-linked proteins37. The
transcription factors nuclear factor (NF)-kB and activation protein
(AP)-1 have been implicated in OA and are downregulated by
glucosamine38,39. In OA, episodic synovial inﬂammation at the
clinical stage is a well-documented phenomenon and is believed to
be involved in disease progression in OA1,40. Inﬂammatory changes
associated with the ACLT model include joint effusion and synovial
membrane hyperplasia, which represent important mechanisms of
joint pain in patients with OA41. In the present study, moderate
synovitis was noted in ACLT knees, and glucosamine administration
could decrease the severity of synovitis (Table II). Joint width could
be measured in patients to determine the extent of tissue swelling
as an index of inﬂammation19. Oral administration of glucosamine
inhibited swelling in both hind paws of mice in which Freund’s
complete adjuvant arthritis was induced42. In the present study, the
OAþ glucosamine group showed a smaller increase in knee joint
width as compared to the OA group (Fig. 2). Oral glucosamine may
therefore decrease inﬂammation in the ACLT knee. Taken together,
the above studies support a role for glucosamine in the protection
of the cartilage matrix and chondrocyte metabolism, suggesting
a possible mechanism by which glucosamine may help to alleviate
clinical signs and retard progression of OA.
MAPKs are activated in joint diseases10,15, and its inhibitors
would attenuate arthritis-induced NF-kB activation and upregula-
tion of proinﬂammatory inducible nitric oxide synthase (iNOS) and
COX-2 in rats43,44. p38 and JNK are phosphorylated in response to
proinﬂammatory cytokines such as TNF-a and IL-1b45, resulting in
activation of transcription factors, including AP-1 complex46, which
are involved in expression of MMPs and aggrecanase47,48 Inhibitors
of JNK, p38, and ERK pathways downregulate IL-1-induced COX-2
expression and PGE2 production in human chondrocytes49. Brown
et al. reported that p38 inhibitor acts as a potential therapeutic for
the treatment of joint degeneration and pain associated with OA15.
The ERK pathway is critical in transducing the IL-1b and TNF-a
signal to induce expression of MMPs responsible for cartilage
destruction50. Glucosamine inhibited IL-1b-stimulated MMP-1,MMP-3, and MMP-13 production in human chondrocytes by inhi-
bition of JNK and p38 phosphorylation39. Glucosamine is capable of
inhibiting iNOS and COX-2 expression in lipopolysaccharide (LPS)-
induced RAW264.7 cells via attenuation of NF-kB signaling by p38
and JNK, but not by ERK13. In the present study, p38 and JNK
expression was increased in the OA group, but ERK expression
showed no signiﬁcant difference between the OA and control
groups (Figs. 4e6). Treatment with glucosamine could decrease the
expression of p38 and JNK in OA cartilage chondrocytes (Figs. 4 and
5). More interestingly, treatment with glucosamine sulfate
increased ERK expression in the OAþ glucosamine group and
glucosamine alone groups of rats (Fig. 6), and this is the ﬁrst ﬁnding
that treatment with glucosamine sulfate could increase ERK
expression in the chondrocytes of OA and naïve rats chondrocytes.
Our observation was partially in line with previous report that in
a dog model of ACLT-induced OA, p38, JNK, and ERK were all acti-
vated to a greater degree in OA compared with normal tissue14.
Another report documented that phosphorylation levels of p38 and
JNKwere higher in OA cartilage than in normal tissue, whereas ERK
was found in both10,11. The reasons for these discrepancies with our
results regarding ERK in OA are presently unclear but are most
likely due to cell-type differences or to differences in experimental
conditions. We suppose that p38, JNK, and ERK might, at least
partially, play a role in OA development and nociception in rat OA.
These ﬁndings support a theory that attenuation of MAPK signaling
can lead to modulation of nociceptive transmission in arthritis.
However, the exact mechanism of MAPK activity on pain reduction
in OA needs further study.
In conclusion, oral glucosamine sulfate can attenuate the
development of OA and associated nociceptive behavior such as
mechanical allodynia and weight-bearing distribution, in an
experimental rat OAmodel. More interestingly, glucosamine sulfate
inhibited p38 and JNK but enhanced the expression of ERK in the
articular cartilage in the experimental OA model. These ﬁndings
may have the way for further investigations of glucosamine sulfate
as a potentially therapeutic target for the treatment of the
inﬂammatory component in OA.
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